IL319996A - Use of long-acting fluticasone propionate injectable suspensions for treating and preventing inflammations of the gastrointestinal tract - Google Patents

Use of long-acting fluticasone propionate injectable suspensions for treating and preventing inflammations of the gastrointestinal tract

Info

Publication number
IL319996A
IL319996A IL319996A IL31999625A IL319996A IL 319996 A IL319996 A IL 319996A IL 319996 A IL319996 A IL 319996A IL 31999625 A IL31999625 A IL 31999625A IL 319996 A IL319996 A IL 319996A
Authority
IL
Israel
Prior art keywords
injections
pharmaceutical composition
corticosteroid
esophagus
ring
Prior art date
Application number
IL319996A
Other languages
English (en)
Hebrew (he)
Inventor
James Helliwell
Amanda Malone
Murray Webb
James Price
Troy Loss
Nicola Price
Paul Brennan
Original Assignee
Eupraxia Pharmaceuticals Inc
James Helliwell
Amanda Malone
Murray Webb
James Price
Troy Loss
Nicola Price
Paul Brennan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eupraxia Pharmaceuticals Inc, James Helliwell, Amanda Malone, Murray Webb, James Price, Troy Loss, Nicola Price, Paul Brennan filed Critical Eupraxia Pharmaceuticals Inc
Publication of IL319996A publication Critical patent/IL319996A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL319996A 2022-10-04 2023-10-03 Use of long-acting fluticasone propionate injectable suspensions for treating and preventing inflammations of the gastrointestinal tract IL319996A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263413167P 2022-10-04 2022-10-04
PCT/US2023/075874 WO2024077017A1 (fr) 2022-10-04 2023-10-03 Utilisation de suspensions injectables de propionate de fluticasone à action prolongée pour le traitement et la prévention d'inflammations du tractus gastro-intestinal

Publications (1)

Publication Number Publication Date
IL319996A true IL319996A (en) 2025-06-01

Family

ID=88695541

Family Applications (1)

Application Number Title Priority Date Filing Date
IL319996A IL319996A (en) 2022-10-04 2023-10-03 Use of long-acting fluticasone propionate injectable suspensions for treating and preventing inflammations of the gastrointestinal tract

Country Status (9)

Country Link
EP (1) EP4598506A1 (fr)
JP (1) JP2025533837A (fr)
KR (1) KR20250091219A (fr)
CN (1) CN119968199A (fr)
AU (1) AU2023356957A1 (fr)
CA (1) CA3268201A1 (fr)
IL (1) IL319996A (fr)
MX (1) MX2025003653A (fr)
WO (1) WO2024077017A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240424000A1 (en) * 2023-06-26 2024-12-26 Eupraxia Pharmaceuticals Inc. Long-acting intra-articular dosage forms containing fluticasone propionate and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63122620A (ja) 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
EP0535937B2 (fr) 1991-10-01 2008-05-21 Takeda Chemical Industries, Ltd. Préparation à base de microparticules à libération prolongée et production de celle-ci
EP1585500B8 (fr) 2002-12-20 2017-07-26 Auritec Pharmaceuticals Particules enrobees destinees a l'administration prolongee d'ingredients pharmaceutiques
EP3970726A1 (fr) * 2010-06-24 2022-03-23 ViroPharma Biologics LLC Procédés de traitement de l'inflammation de l' sophage
BR112015024234B1 (pt) 2013-03-21 2022-11-16 Eupraxia Pharmaceuticals USA LLC Composição farmacêutica de liberação sustentada injetável, uso da mesma para diminuir inflamação ou controlar dor e método para formar micropartículas revestidas
WO2016205172A1 (fr) * 2015-06-15 2016-12-22 Banner Life Sciences Llc Pastilles molles comprenant des corticostéroïdes
US20220168665A1 (en) 2019-04-10 2022-06-02 Eupraxia Pharmaceuticals Inc. Process for making drug crystals of desired size distribution and morphology

Also Published As

Publication number Publication date
CA3268201A1 (fr) 2024-04-11
KR20250091219A (ko) 2025-06-20
AU2023356957A1 (en) 2025-03-27
EP4598506A1 (fr) 2025-08-13
WO2024077017A1 (fr) 2024-04-11
JP2025533837A (ja) 2025-10-09
CN119968199A (zh) 2025-05-09
MX2025003653A (es) 2025-07-01

Similar Documents

Publication Publication Date Title
US20250090467A1 (en) Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
MX2014008895A (es) Formulaciones de esteroides neuroactivos y metodos para tratar trastornos del cns.
EP2958579A1 (fr) Formulations de stéroïdes administrées par voie orale destinées à être utilisées pour le traitement d'une fibrose intestinale
CN113117092A (zh) 一种非水缓释递药系统
CN117715625A (zh) 用于治疗晶体和非晶体相关急性炎症性关节炎的包含秋水仙碱的关节内注射用剂型
CN121013711A (zh) 用于治疗关节病诸如骨关节炎的包含秋水仙碱的关节内注射剂型
CN1284524C (zh) 固体脂质纳米粒在制备用于离子导入透皮给药的药物中的应用
AU2023356957A1 (en) Use of long-acting fluticasone propionate injectable suspensions for treating and preventing inflammations of the gastrointestinal tract
CN102133180B (zh) 一种甾体5α-还原酶抑制剂长效注射制剂及其制备方法
CN118891032A (zh) 用于延长释放非诺贝特的微球
JP2006028031A (ja) 経粘膜吸収用薬物封入ナノ粒子
US10835489B2 (en) Modified release formulations of mycophenolate mofetil
WO2005079703A1 (fr) Systemes de distribution polymeres biocompatibles pour la liberation controlee de quinazolinones
CN112121028B (zh) 一种辛伐他汀固体纳米粒制剂及其制备方法
CN117717524B (zh) 一种负载精氨酸的白蛋白基缓释微球及其制备方法与应用
JP2000143538A (ja) 免疫調節剤を含有する医薬組成物
HK40072275A (en) Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
CN120417887A (zh) 在晶体和非晶体相关的急性炎症性关节炎的治疗中包含秋水仙碱和麻醉剂的用于关节内注射的剂型
HK40128727A (zh) 在晶体和非晶体相关的急性炎症性关节炎的治疗中包含秋水仙碱和麻醉剂的用於关节内注射的剂型